ACP
GRCE

Acuta Capital Partners’s Grace Therapeutics GRCE Stock Holding History

Acuta Capital Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,917
Closed -$1.52M – 42
2019
Q4 		$1.52M Buy
+12,917
New +$1.28M 0.38% 34

Other funds holding GRCE

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JLBC
J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Acuta Capital Partners's GRCE Position: Q1 2020 in Review

Acuta Capital Partners sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 12,917 shares — an estimated $1.52M sold.

Acuta Capital Partners first reported a position in GRCE in Q4 2019 and held it in 1 quarter. The position peaked at $1.52M in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

  • Acuta Capital Partners reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 12,917 Grace Therapeutics shares in Q1 2020, an estimated $1.52M.
  • Acuta Capital Partners first reported a position in Grace Therapeutics in Q4 2019 and held it in 1 quarter.
  • Acuta Capital Partners's Grace Therapeutics position peaked at $1.52M in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.